Osimertinib continues to bring in great results!
Wild excitement at the ASCO (American Society of Clinical Oncology)conference on 4th June as Astra Zeneca presented the latesT trial data for adjuvant Osimertinib. I attach the link to the Astra Zeneca press release for those of you who want to know more about the Adaura trial. In essence, the excitement has been getting the 5 year Overall Survival data and 88% is a figure we will all celebrate.
Adjuvant Osimertinib (ie post surgery) is currently available via the Cancer Drug Fund (CDF) in the UK. The NICE recommendation for use within the CDF means that the drug shows promising results in trials but, there isn't enough evidence for a 'Yes' decision at the moment. The aim of the CDF is to give doctors quick access to new treatments and more time to collect evidence about how well the drug works. This means that at the moment as an NHS patient, your Oncologist has to apply for adjuvant Osimertinib before they can prescribe it.
Tagrisso achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
This new trial data will hopefully accelerate the approval by NICE and the Scottish Medicines Consortium of Osimertinib as the accepted Standard of Care in the NHS for EGFR+ NSCLC Stage 1B - IIIA patients who have had their tumours completely removed.
Having spoken to a journalist prior to the trial presentation, we were able to add a case study and quote from the charity to the press release and happily, these were picked up by 6 daily newspapers on Monday morning! Thanks to Natasha Loveridge for your speedy responses to my late Saturday night requests!
Excellent PR for EGFR+ and the Charity!